List of Excipients in Branded Drug AUROVELA 1.5/30

Generic Drugs Containing AUROVELA 1.5/30

Company	Ingredient	NDC	Excipient
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-935	.ALPHA.-TOCOPHEROL
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-935	CELLULOSE, MICROCRYSTALLINE
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-935	CROSCARMELLOSE SODIUM
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-935	LACTOSE MONOHYDRATE
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-935	MAGNESIUM STEARATE
Aurobindo Pharma Limited	norethindrone acetate and ethinyl estradiol	65862-935	POVIDONE K30

What are the Most Frequently-Used Excipients in AUROVELA 1.5/30?

# Of NDCs	Excipient
1	.ALPHA.-TOCOPHEROL
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	LACTOSE MONOHYDRATE
1	MAGNESIUM STEARATE
1	POVIDONE K30

Aurovela 1.5/30 Excipient Strategy and Commercial Opportunities

Last updated: August 24, 2026

Aurovela 1.5/30 is a generic combined oral contraceptive containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg per tablet. Its commercial opportunity is primarily a cost, supply, packaging, and lifecycle-management opportunity rather than a conventional patent-protected innovation opportunity. The strongest excipient strategy is a robust, low-cost immediate-release tablet platform that supports reliable dissolution, manufacturing continuity, and potential line extensions such as 28-day packaging, alternative colors, and patient-oriented formulations.

What is Aurovela 1.5/30?

Aurovela 1.5/30 is an oral contraceptive tablet containing:

Attribute	Product detail
Active ingredient 1	Norethindrone acetate, 1.5 mg
Active ingredient 2	Ethinyl estradiol, 0.03 mg
Dosage form	Immediate-release oral tablet
Therapeutic category	Combined hormonal contraceptive
Product type	Generic prescription drug
Reference-product class	Norethindrone acetate and ethinyl estradiol tablets
Pack configurations	Typically 21 active tablets, with packaging configurations varying by manufacturer
Manufacturer	Aurobindo Pharma Limited or an affiliated commercial entity, depending on market presentation
FDA pathway	Abbreviated New Drug Application, or ANDA, generic pathway

The product is pharmacologically sensitive to dose uniformity because ethinyl estradiol is present at a low dose. Small blend-segregation or assay-uniformity problems can have a material effect on batch release and regulatory compliance.

What excipients are used in Aurovela 1.5/30?

Public product labeling identifies conventional tablet excipients for the Aurovela product family, including lactose monohydrate, pregelatinized starch, povidone, magnesium stearate, and other tableting excipients depending on the specific strength and presentation. The marketed product label remains the controlling source for the exact inactive-ingredient composition of Aurovela 1.5/30. [1]

The formulation architecture is consistent with a conventional compressed, immediate-release tablet:

Excipient function	Likely formulation role
Lactose monohydrate	Diluent and compressibility aid
Pregelatinized corn starch	Binder, disintegrant, and processing aid
Povidone	Binder and granulation aid
Magnesium stearate	Lubricant
Sodium starch glycolate or equivalent disintegrant, where used	Tablet breakup and dissolution support
Talc, where used	Flow and anti-adherence control
Colorants, where used	Product identification and brand differentiation

The low-strength ethinyl estradiol component creates a content-uniformity challenge. The formulation must distribute a small quantity of potent active ingredient throughout a much larger excipient matrix. Premixing, geometric dilution, controlled granulation, and blend-time validation are therefore more commercially important than adding expensive excipients.

How should the excipient strategy for Aurovela 1.5/30 be designed?

The preferred strategy is a conventional, scalable formulation with four priorities: content uniformity, rapid and consistent disintegration, low manufacturing cost, and supply-chain resilience.

Content uniformity

Norethindrone acetate is present at a comparatively high dose, while ethinyl estradiol is present at 30 mcg. The formulation should use a validated low-dose premix or ordered blending process. Critical controls include:

• Particle-size matching between active ingredients and major diluents.
• Low-segregation excipient grades.
• Controlled addition of ethinyl estradiol.
• Validated blend sampling plans.
• Narrow control of bulk density and flow properties.
• In-process weight and assay monitoring.

Direct compression may reduce processing steps, but it requires highly consistent powder flow and compressibility. Wet granulation can improve content uniformity and tablet robustness, although it adds drying, solvent, equipment, and process-control requirements.

Disintegration and dissolution

Immediate-release performance should remain predictable across normal manufacturing variation. Excessive hydrophobic lubrication can slow dissolution, particularly if magnesium stearate is overmixed or used at a high concentration.

The excipient program should control:

• Magnesium stearate concentration and mixing time.
• Starch or superdisintegrant grade.
• Granule moisture.
• Tablet hardness and friability.
• Compression force.
• Coating weight, if a coating is used.

Aurovela 1.5/30 is not a product where a slow-release profile creates a commercial advantage. The principal objective is rapid and reproducible release that remains within the approved dissolution profile.

Moisture management

Lactose and starch-based formulations can respond to humidity, temperature, and storage duration. Moisture may affect tablet hardness, friability, disintegration, and chemical stability.

Commercial controls should include:

• Moisture-barrier blister or bottle packaging.
• Hygroscopicity screening for each excipient grade.
• Stability testing in the intended market container.
• Defined granule or blend moisture limits.
• Supplier controls for lactose and starch water content.

Packaging improvements may generate more practical value than replacing established excipients with premium materials.

Lubrication and compression

Magnesium stearate is inexpensive and widely available, but excessive lubrication can reduce tablet tensile strength and delay dissolution. A commercial formulation should establish a narrow operating range for:

• Lubricant concentration.
• Lubrication time.
• Blender fill level.
• Compression speed.
• Ejection force.
• Tablet hardness.

A robust design-of-experiments program can identify a formulation that tolerates normal variation in lubricant mixing and compression without compromising dissolution or content uniformity.

What commercial opportunities exist for Aurovela 1.5/30 excipients?

The largest opportunity is not a premium excipient claim. It is a reliable generic product with lower manufacturing risk and better supply continuity.

1. Lactose-reduced or lactose-free positioning

A lactose-free version could target patients who avoid lactose or experience excipient-related intolerance. This would require a replacement diluent, such as microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed excipient.

The main technical risks are:

• Different tablet density and size.
• Altered blend uniformity.
• Changed dissolution.
• New compression behavior.
• New stability profile.
• Potential need for a separate ANDA formulation and bioequivalence package.

A lactose-free product could have commercial value, but the opportunity is likely niche unless supported by a payer, pharmacy, or patient-access strategy.

2. Excipient supply-chain diversification

Aurovela 1.5/30 uses commodity excipients with multiple global suppliers. A manufacturer can reduce interruption risk by qualifying alternate grades of:

• Lactose monohydrate.
• Pregelatinized starch.
• Povidone.
• Magnesium stearate.
• Disintegrant.
• Packaging polymers and foils.

This approach may not create visible product differentiation, but it can reduce batch delays, deviation investigations, and shortage exposure. For a low-margin contraceptive product, continuity is a commercial advantage.

3. Smaller tablet or improved swallowability

A lower-volume excipient system could reduce tablet size. Possible approaches include higher-density diluents, optimized granulation, or direct compression. The commercial value is limited by the need to preserve:

• Dose uniformity.
• Mechanical strength.
• Dissolution.
• Stability.
• Manufacturability at high speed.

A smaller tablet could support patient preference, but a materially different dosage form would require regulatory assessment and may not fit within the existing approved product presentation.

4. Color and product-identification strategy

Colorants can distinguish strengths and reduce dispensing errors across norethindrone acetate and ethinyl estradiol products. The opportunity is operational rather than therapeutic.

A manufacturer could use:

• Strength-specific tablet colors.
• Embossing or debossing.
• Film coating for improved visual identification.
• Packaging that clearly separates active and placebo tablets in 28-day packs.

Colorants create supplier and regulatory dependencies. Any color change must be assessed for product sameness, stability, dissolution, and labeling consistency.

5. 28-day packaging and adherence support

Aurovela 1.5/30 can be commercially packaged in a 28-day regimen format. Depending on the product presentation, this may involve 21 active tablets with seven reminder tablets, or a packaging system that instructs patients to follow a seven-day tablet-free interval.

Commercial opportunities include:

• Calendar blister packs.
• Unit-dose packaging.
• Retail pharmacy adherence packaging.
• Direct-to-consumer mail-order packs.
• Digital refill synchronization.
• Multi-month dispensing.

Packaging changes may produce greater market impact than modest excipient substitutions because oral-contraceptive use is sensitive to missed doses and refill interruptions.

What formulations are protected by patents?

Aurovela 1.5/30 is a generic product, and the principal formulation is based on an established oral-contraceptive composition. Publicly available FDA materials generally do not identify a commercially meaningful, product-specific patent barrier that would prevent generic manufacture of the basic norethindrone acetate/ethinyl estradiol tablet. The Orange Book must be reviewed for the applicable reference product and any listed patents or exclusivity. [2]

Potential intellectual-property areas include:

IP category	Relevance to Aurovela 1.5/30
Active-ingredient composition	Usually mature and commercially unrestrictive
Basic immediate-release tablet	Limited opportunity for blocking claims
Excipient combination	Potentially protectable only if novel and non-obvious
Manufacturing process	May protect granulation, blending, coating, or control methods
Packaging system	Possible protection for adherence-oriented packaging
Method of use	Generally tied to contraceptive use, regimen, or noncontraceptive indications
Combination with iron tablets	Relevant to products containing ferrous fumarate, not necessarily the plain 1.5/30 product
Brand and trade dress	Trademark and packaging rights remain relevant

A new excipient combination would need a credible technical effect, such as improved content uniformity, dissolution robustness, stability, or manufacturability. A simple substitution of lactose with another conventional diluent would face a higher obviousness risk.

When does Aurovela 1.5/30 lose exclusivity?

Aurovela 1.5/30 is already a generic product and does not have the exclusivity profile of a newly approved branded drug. The relevant commercial issue is continuing generic competition, not an upcoming loss of exclusivity.

The reference-product market for norethindrone acetate and ethinyl estradiol tablets has been subject to generic competition for years. Any remaining patent analysis should distinguish:

1. Patents listed for the reference product.
2. Patents owned by the generic manufacturer.
3. Manufacturing patents not listed in the Orange Book.
4. Packaging or device patents.
5. Patents covering separate formulations or therapeutic uses.

A generic manufacturer can enter after satisfying ANDA requirements and addressing applicable Orange Book patents, regulatory exclusivity, and litigation risk. [2,3]

What is the Orange Book status of Aurovela 1.5/30?

The Orange Book primarily lists patents and exclusivity for approved reference listed drugs. Aurovela 1.5/30, as a generic, is not normally analyzed as having its own Orange Book exclusivity period. Its regulatory position depends on the ANDA approved against the applicable reference product and on the status of any listed patents associated with that reference product.

For commercial diligence, the relevant checks are:

• Reference listed drug identification.
• Approval pathway and ANDA number.
• Listed patents for the reference product.
• Pediatric exclusivity.
• Three-year, five-year, or orphan exclusivity, if applicable.
• Therapeutic-equivalence rating.
• Current marketing status.
• Product discontinuation or shortage notices.

FDA’s Drugs@FDA and Orange Book databases are the controlling public sources for these determinations. [2,4]

Which companies are challenging or competing with Aurovela 1.5/30?

Competition comes from several groups:

• Other generic manufacturers of norethindrone acetate and ethinyl estradiol tablets.
• Branded and authorized-generic suppliers.
• Alternative combined oral contraceptives.
• Progestin-only pills.
• Long-acting reversible contraceptives.
• Transdermal patches, vaginal rings, implants, and intrauterine systems.

Relevant competing products may contain different progestins, including levonorgestrel, drospirenone, desogestrel, or norgestimate. These products are not direct pharmaceutical equivalents, but they compete for the same contraceptive prescribing and dispensing volume.

The most direct generic competitors are likely to compete on:

• Wholesale acquisition cost.
• Retail pharmacy contract access.
• Product availability.
• Pack size.
• Refill reliability.
• Therapeutic-equivalence rating.
• Wholesaler and group-purchasing arrangements.

What generic entry risks exist for Aurovela 1.5/30?

The product has low legal entry risk relative to newer pharmaceutical products, but it has meaningful commercial and operational risks.

Price erosion

Multiple generic suppliers can compress pricing. A differentiated excipient strategy will not protect against price erosion unless it produces a clear procurement or adherence benefit.

Shortage and discontinuation risk

Low-margin oral contraceptives may be vulnerable to supplier consolidation, raw-material disruption, manufacturing deviations, and contract-manufacturing changes. Alternate excipient suppliers and validated second-source processes reduce this exposure.

Regulatory risk

Changes in excipient source, grade, colorant, manufacturing process, or packaging may require regulatory reporting or prior approval. The change category depends on its effect on product quality and the applicable FDA postapproval-change guidance. [5]

Product liability and labeling risk

Combined hormonal contraceptives carry known warnings relating to thromboembolic and cardiovascular risks. Excipient changes do not remove the need for complete labeling controls, pharmacovigilance, and complaint surveillance.

How strong is the patent estate for Aurovela 1.5/30?

The patent estate is likely weak as a blocking estate and stronger as a potential process or lifecycle estate.

Patent strategy	Commercial strength
Basic norethindrone acetate/ethinyl estradiol composition	Low
Conventional lactose-starch tablet	Low
Novel content-uniformity process	Moderate if supported by unexpected results
Moisture-stable formulation	Moderate in a defined technical context
Lactose-free formulation	Moderate, but obviousness risk is material
Adherence packaging	Moderate, usually narrow
New therapeutic indication	Potentially stronger, subject to clinical evidence
Manufacturing controls and process parameters	Potentially useful but difficult to enforce

A credible formulation patent would need more than a list of known excipients. It should define a specific composition or process and demonstrate a measurable advantage over conventional formulations.

What patent litigation affects Aurovela 1.5/30?

No major product-specific litigation can be identified from the available information as a central commercial constraint for the established generic product. The principal litigation risk would arise if a new entrant challenged patents associated with the reference product or if a manufacturer sought to launch a differentiated formulation covered by a third-party process, packaging, or formulation patent.

Paragraph IV litigation is more relevant to an ANDA applicant entering before expiration of an Orange Book-listed reference-product patent. It is not normally a continuing barrier for an already marketed generic unless additional patent claims or regulatory exclusivities remain active. [3]

How does Aurovela 1.5/30 compare with Aurovela Fe?

Aurovela Fe adds ferrous fumarate reminder tablets to the contraceptive regimen. The excipient strategy differs because the iron tablets introduce:

• Ferrous fumarate compatibility requirements.
• Potential color and staining issues.
• Different taste and gastrointestinal tolerability considerations.
• Additional tablet-composition and stability controls.
• More complex packaging and identification requirements.

Attribute	Aurovela 1.5/30	Aurovela Fe
Active contraceptive tablets	Yes	Yes
Iron reminder tablets	No	Yes
Formulation complexity	Lower	Higher
Excipient and stability burden	Lower	Higher
Adherence packaging opportunity	Moderate	High
Manufacturing cost	Lower	Higher
Substitution risk	Direct generic competition	Direct and cross-product competition

The plain 1.5/30 product may be easier to manufacture and supply. The Fe version may support more packaging differentiation but has additional quality-control requirements.

What regulatory path applies to an excipient change?

For an approved generic product, the regulatory impact depends on the change.

A change in excipient supplier or grade may be manageable if the new material meets the same specification and the finished product remains equivalent. A change in excipient type, concentration, tablet composition, or manufacturing process may require comparative dissolution, stability data, analytical comparability, and potentially a bioequivalence study.

The regulatory program should assess:

• Pharmaceutical equivalence.
• Impurity profile.
• Content uniformity.
• Dissolution similarity.
• Tablet physical properties.
• Stability.
• Container-closure compatibility.
• Labeling impact.
• Annual-reportable, change-reportable, or prior-approval classification.

FDA’s ANDA postapproval-change framework should guide the filing strategy. [5]

What is the revenue exposure and commercial outlook?

Aurovela 1.5/30 is a high-volume, low-differentiation generic category. Revenue is exposed to:

• Number of approved generic suppliers.
• Contract pricing.
• Medicaid and commercial formulary placement.
• Pharmacy benefit manager negotiations.
• Wholesaler inventory levels.
• Manufacturing continuity.
• Product availability during competitor shortages.

The most defensible commercial opportunities are:

1. Secure multi-source excipient supply.
2. Reduce manufacturing deviations and batch failures.
3. Offer reliable 21-day and 28-day packaging.
4. Evaluate lactose-free positioning.
5. Improve unit-dose and mail-order formats.
6. Use process patents selectively for genuine manufacturing advantages.
7. Develop a broader hormonal-contraceptive portfolio around the same tablet platform.

The commercial case for a premium excipient is weak unless it lowers total cost, improves supply continuity, or supports a meaningful patient-access claim.

Key Takeaways

• Aurovela 1.5/30 is a generic immediate-release tablet containing norethindrone acetate 1.5 mg and ethinyl estradiol 30 mcg.
• Its core excipient platform is conventional and cost-efficient.
• The primary technical risk is uniform distribution of the low-dose ethinyl estradiol component.
• Lactose, starch, povidone, magnesium stearate, and disintegrant selection should be optimized for uniformity, dissolution, and manufacturing resilience.
• The strongest commercial opportunities are supply-chain diversification, packaging, adherence support, and selected lactose-free or smaller-tablet line extensions.
• The basic product has limited blocking-patent value. New patent value would likely come from validated manufacturing, stability, or packaging improvements.
• Orange Book and ANDA analysis should focus on the applicable reference product, listed patents, therapeutic equivalence, and any remaining exclusivity.
• Generic price erosion is a larger business risk than patent expiry.
• Aurovela Fe has a more complex excipient and manufacturing profile because of ferrous fumarate reminder tablets.

FAQs

Can Aurovela 1.5/30 be reformulated without a new clinical trial?

Some excipient-source or grade changes may be handled through postapproval documentation and comparative quality data. A material composition or process change may require additional bioequivalence evidence under FDA requirements.

Is a lactose-free version of Aurovela 1.5/30 commercially attractive?

It may address a defined patient segment, but the opportunity is likely niche. The reformulation must preserve dose uniformity, dissolution, stability, tablet size, and regulatory comparability.

Does Aurovela 1.5/30 have a biosimilar risk?

No. Aurovela 1.5/30 is a small-molecule oral contraceptive, not a biologic. The relevant competitive risk is generic substitution, not biosimilar entry.

Can excipients be patented in a generic contraceptive tablet?

Yes, but a patent generally requires a novel and non-obvious composition or process with a defensible technical effect. Conventional excipient substitutions are vulnerable to obviousness challenges.

Which excipient has the greatest effect on Aurovela 1.5/30 dissolution?

The highest-impact variables are usually disintegrant performance, lubricant level and mixing time, granule moisture, compression force, and any coating. The effect depends on the final formulation and manufacturing process.

References

1. DailyMed. (n.d.). Aurovela-1.5/30: Norethindrone acetate and ethinyl estradiol tablet. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions: Refuse-to-receive standards. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Food and Drug Administration. (2014). Changes to an approved NDA or ANDA: Guidance for industry. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/supplements-anda-or-nda】【。